Mycophenolate sodium

Drug Profile

Mycophenolate sodium

Alternative Names: EC-MPS; ERL 080; ERL 080A; Mycophenolic acid - Novartis; Mycophenolic acid delayed-released tablets - Novartis; Myfortic

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Novartis
  • Developer Novartis; University of Pittsburgh
  • Class Benzofurans; Small molecules
  • Mechanism of Action Immunosuppressants; Inosine monophosphate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lupus nephritis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Renal transplant rejection
  • Phase II Liver transplant rejection
  • No development reported Heart transplant rejection; Lupus nephritis

Most Recent Events

  • 09 Jan 2014 First generic equivalent available in USA for Renal transplant rejection
  • 18 Nov 2009 Novartis completes a phase II trial in Lupus nephritis in Hungary, France, Great Britain, Greece, Denmark, Italy and Spain (EudraCT2006-002107-13)
  • 04 Jun 2008 Pharmacokinetics data from a trial in de novo renal transplant patients presented at the 8th Joint Congress of the American Society of Transplant Surgeons (ASTS) and the American Society of Transplantation (AST) (ATC-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top